An interventional study of Sham (No Treatment) and NMES in Muscle Wasting, sponsored by Wageningen University. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Wageningen University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Muscular Atrophy with a site in Netherlands — 3 open to participants now, 5 under way, 2 of them phase 3. Muscular Atrophy · Netherlands.
Among the 21 studies in Muscular Atrophy with a site in Netherlands, this one is the 11th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 20th registered.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
Browse Muscular Atrophy studies →3 of the 21 studies in Muscular Atrophy with a site in Netherlands are open now. Recruiting first, the newest first:
Wageningen University · Sites in Netherlands
Ages 18–40 · Healthy volunteers
Maasstad Hospital · Sites in Netherlands
Ages 18–65
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 6
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is close to the median of 40 across 327 interventional studies indexed under Muscular Atrophy.
Median enrollment 55 across the 18 interventional studies, 23 across the 3 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 7 most frequent:
Wageningen University is the lead sponsor of 153 studies on the registry; 15 are open to participants now.
Wageningen University has 2 studies filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
1 of the studies in Muscular Atrophy with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062562Wageningen UniversityThe Effect of Repeated Whole-body NMES Sessions With or Without Protein Intake on Muscle Protein Synthesis During 3 Days of Bed Rest in Healthy Young Volunteers | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Muscular Atrophy with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to examine the effect of whole-body electrostimulation with protein intake on muscle protein synthesis, muscle mass and function during bed rest in healthy young adults (18-35 years). The main questions to answer are:
Researchers will compare sham electrical electrostimulation, electrical stimulation and electrical stimulation + protein groups to see if whole-body electrostimulation combined with protein intake offers the greatest improvement in muscle protein metabolism and muscle preservation.
Participants will:
Undergo 3 days of bed rest while receiving one of the following interventions:
Patients admitted to the hospital often experience prolonged bed rest, which can lead to rapid muscle loss and weakness. In the intensive care unit (ICU), this condition, known as ICU-acquired weakness (ICU-AW), affects up to 50% of patients and can lead to longer mechanical ventilation times, increased morbidity, and a reduced quality of life after hospital discharge. One of the key reasons for muscle loss during bed rest is an impaired response to dietary protein, which normally helps maintain muscle mass.
Neuromuscular electrical stimulation (NMES) is a method that uses small electrical currents to stimulate muscle contractions, potentially counteracting muscle loss during periods of inactivity. Previous research has shown that NMES applied to the quadriceps muscles can reduce muscle loss in sedated patients and improve muscle protein synthesis in individuals with type 2 diabetes. However, the effects of whole-body NMES in combination with timed protein intake on muscle protein metabolism during bed rest are still unknown.
This study aims to investigate the impact of both a single session and repeated sessions of whole-body NMES, with or without subsequent protein intake, on muscle protein synthesis rates, muscle mass, and function during 3 days of bed rest in healthy young adults.
Study Design:
This is a randomized, placebo-controlled clinical trial with three parallel groups. Participants will be randomly assigned to one of the following groups:
Study Procedures:
Participants will be healthy adults (18-35 years, male and female) and will undergo the following procedures:
This study will provide critical insights into how NMES and protein intake can help counteract muscle loss and weakness during hospitalization and may contribute to the development of more effective rehabilitation strategies for ICU and bedridden patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any diagnosed cardiovascular (heart) disease or high blood pressure (≥140 mmHg systolic and/or
≥90 mmHg diastolic)
arthritis, spasticity/rigidity, all neurological disorders and paralysis)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sham-NMES with standard nutrition
Other: Sham (No Treatment) · Other: Standard nutrition
Whole-body NMES stimulation with standard nutrition
Other: NMES · Other: Standard nutrition
Whole-body NMES with a 20g protein bolus on top of the standard nutrition
Other: NMES · Dietary Supplement: Protein bolus (20g) · Other: Standard nutrition
A placebo treatment in which no actual electrical stimulation is delivered, serving as a control for the active NMES.
Active neuromuscular electrical stimulation applied to the entire body to induce muscle contractions through small electric currents.
A bolus dose of 20 grams of protein provided after the NMES intervention to assess the combined effect of muscle stimulation and protein intake on muscle protein metabolism.
Provision of a normal Western standardized diet.
Cumulative myofibrillar fractional synthesis rate
A measure of muscle protein synthesis between two given time points.
Time frame: Habitual MPS (Day -2 to Day 0), Acute effect of NMES (+protein bolus) (0 hours to 5 hours on Day 0), Bedrest MPS (Day 0 to Day 3),
Quadriceps Muscle Layer Thickness
Assessed using ultrasound, this measures changes in muscle size, indicating muscle loss or preservation during bed rest and NMES intervention.
Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6
Body Composition
Evaluates muscle mass to determine overall changes.
Time frame: Day 0 and Day 3.
Body composition
Evaluates fat distribution to determine overall changes.
Time frame: Time Frame: Day 0 and Day 3.
Quadriceps Muscle Function
Assessed via a leg dynamometer.
Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6
Quadriceps Muscle Strength
Assessed via a leg dynamometer.
Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6
Handgrip Strength
Assessed via a hand dynamometer.
Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6
Whole-Body Nitrogen Balance
The balance between nitrogen intake (from dietary protein) and nitrogen loss (through urine and other excretions)
Time frame: Day 0 to Day 3
Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.
Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 24 months is close to that.
Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.